依达拉奉治疗急性脑梗死42例疗效分析

目的观察依达拉奉治疗急性脑梗死（ACI）的临床疗效及安全性。方法采用随机对照试验，选择发病72h内的ACI患者83例，分为依达拉奉治疗组42例和对照组41例，按两组治疗前后神经功能缺损（CSS）评分及日常生活能力量表（ADL）记分的变化为主要疗效判断标准进行对比分析。结果治疗第14天和第60天CSS评分、ADL评分治疗组和对照组比较差异均有统计学意义（P〈0．05），各组治疗前、治疗第14天和第60天CSS评分、ADL评分差异有统计学意义（P〈0．01），治疗组无明显不良反应。结论依达拉奉治疗急性脑梗死疗效确切，安全可靠。

Curative effect of edaravone on acute cerebral infarction

Objective To observe the clinical effect and safety of edaravone in treatment of acute cerebral infarction(ACI).Methods By randomized control study.83 patients with ACI onset less than 72 h were randomly allocated to the group of edaravone medication(n=42)or controls(n=41).The two groups of patients were observed before and after the medication concerning CSS and activities of daily living(ADL)for evaluating the criteria of out-comes by the score range.Results After 14 d and 60 d of medication.the scores were different with regard to CSS and ADL compared with the controls(P<0.05).The difference was also significant between the two groups at 14th or 60th day before and after the treatment concerning CSS and ADL(P<0.01).No side effects were observed in the patients of medication.Conclusion Edaravone can be effectively and safely used for ACI.